Skip to main content
Equibles
INKT logo

INKT · MiNK Therapeutics, Inc.

Track INKT — free

Use INKT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about INKT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$11.27 +0.27 (+2.45%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the completion of anticipated funding is not entirely within the Company's control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 13, 2026
Market Cap
$57.51M
Shares
5.10M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.27 Open$11.10 Day$10.95–11.50 52W close$8.56–16.30 Avg vol 30d11K Short int94K · 1.8% float · 9.4d Short vol27% Last earningsAug 13, 2026 DataJan 2025–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Jan 28, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 25, 2026 Est · unconfirmed · in 14 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −2%
      below
      Price vs 50-day avg −1%
      below
      RSI (14) 53
      neutral
      MACD trend Positive
      52-week position 35%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Neutral
      1-month return +6%
      trailing
      6-month return 0%
      trailing
      YTD return +1%
      this year
      Relative strength −13%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $11 › 200d $12 — 200d above 50d
      Institutional flow Accumulating
      +22% holders QoQ · +8 funds added
      Insider flow Distributing
      Net -$19.1K over 90 days · 100% sells
      Short interest Falling
      1.84% of float · ▼ -5.5% MoM · 9.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      28 holders — mid 3-yr range
      Squeeze score 59
      elevated · 0–100
      Fundamentals
      Weak
      EPS growth −2%
      Y/Y
      Free cash flow $-6.0M
      Balance sheet $13.4M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 75%
      annualized · 1-yr
      Max drawdown −47%
      past year
      ATR 5.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      0 · 6 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −2% Neutral
      Price vs 50-day avg
      −1% Neutral
      RSI (14)
      53 Neutral
      MACD trend
      Positive Bullish
      52-week position
      35% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $11 › 200d $12 — 200d above 50d
      Institutional flow Accumulating
      +22% holders QoQ · +8 funds added
      Insider flow Distributing
      Net -$19.1K over 90 days · 100% sells
      Short interest Falling
      1.84% of float · ▼ -5.5% MoM · 9.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      28 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $9 Now $11 · 35% Range high $16
      vs 200-day avg -2% vs 50-day avg -1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      INKT
      MiNK Therapeutics, Inc.
      this stock
      		$57.51M +1.1% — — 1.8%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      28
      % held
      4.0%
      Net QoQ
      +77.6K sh
      Top holder
      VANGUARD CAPITAL MANAGEME…
      Held Float
      View
      Held by Funds
      Fund positions
      7
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      94.1K
      Days to cover
      9.4d
      Change
      -5.5K sh
      View
      Short Volume
      Short vol %
      27%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      262
      Value
      $2.9K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      42.6%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$19.1K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-12.5M
      EPS diluted
      $-2.93
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 13, 2026
      This year
      11
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Jan 28, 2025; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      INKT +2.9% +5.7% +0.4% +7.3% +1.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +2.5% +1.3% -13.4% +3.4% -12.8%
      Key facts CIK 1840229 CUSIP 603693201 13F (30d) 28 filings 28 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)